LOSS OF LEAN BODY MASS With a reduction of significant weight often comes a reduction in lean mass (muscle and bones) as well as fat mass
Many people begin GLP-1 drug therapy expecting rapid, dramatic changesbut what they dont realize is that outcomes can vary widely based on factors like metabolism, diet, activity levels, and even how the body individually responds to these medications
due to continuous improvements, product packaging may vary slightly
A systematic review and meta-analysis published in BMC Gastroenterology found that constipation rates with GLP-1 receptor agonists were approximately 2.5 times higher than placebo groups
First: a once-weekly subcutaneous injection of semaglutide 1.0 mg (Ozempic), a glucagon-like peptide 1 analogue, was approved for the treatment of type 2 diabetes, and has proven to reduce the risk of cardiovascular events in people with type 2 diabetes and cardiovascular disease